­
­
­
­

Inventi Impact: Molecular Pharmacology

Articles

  • Inventi:pmp/31409/20
    20(S)-Protopanaxdiol Suppresses the Abnormal Granule-Monocyte Differentiation of Hematopoietic Stem Cells in 4T1 Breast Cancer-Bearing Mouse
    Research 2020 : April - June
    Wen-Qin Guo, Ying-Ge Chen, Rong-Zhen Shi, Kai He, Jian-Feng Wang, Jin-Hui Shao, Jian-Bo Wan, Jian-Li Gao

    Panax notoginseng (PN) has been used as a qi- and blood-activating (Huoxue) drug for thousands of years in China. It has also\nbeen widely used as an anticancer drug at present. As a Huoxue drug, the effect of PN on hematopoietic differentiation in tumorbearing\nbody has been paid more and more attention. Our research found that panax notoginseng saponins (PNS), especially\npanaxadiol saponins (PDS) and its aglucon 20(S)-Protopanaxdiol (PPD), could improve the immunosuppressive state by regulating\nthe abnormal hematopoietic differentiation in a tumor-bearing body by multiple ways����..

    How to Cite this Article
    Attribution/ CC Compliant Citation: Guo, Wen-Qin, et al. \"20 (S)-Protopanaxdiol Suppresses the Abnormal Granule-Monocyte\nDifferentiation of Hematopoietic Stem Cells in 4T1 Breast Cancer-Bearing Mouse.\" Evidence-Based Complementary and Alternative\nMedicine 2020 (2020).\nhttps://doi.org/10.1155/2020/8747023\nhttp://creativecommons.org/licenses/by/4.0/\n\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text